Corporate News
Cumberland Pharmaceuticals Inc. (CPIX)
Stock Performance
The stock closed down 6.69 % during the 24‑hour period ending 10:40 AM Central Europe time on Wednesday, 21 March 2026.
Current trading price: USD 7.96.
Share supply: 15 million.
Market capitalization: USD 107.6 million.
Volume traded in the last 24 hours: USD 603 k.
Since the end of the previous month the stock has fallen 11.73 %.
200‑day simple moving average: USD 5.45.
52‑week high: USD 9.28 (26 August 2026).
52‑week low: USD 1.85 (18 November 2025).
Upcoming Investor Event Cumberland Pharmaceuticals will host a national webcast and conference call on 26 October 2026 at 4:30 p.m. Eastern Time.
The call will provide an update on the company’s ifetroban candidate, which is under investigation as a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
The presentation will include slides that will be posted on the company’s Investor Relations website after the call.
Participants may join the event via webcast (to view slides) or by telephone for audio‑only participation.
The update will also cover the broader clinical development strategy, including programs for systemic sclerosis, idiopathic pulmonary fibrosis, and cancer metastasis.
Key Highlights
The event is intended to inform investors and stakeholders about progress in the DMD program and the company’s overall therapeutic pipeline.
Cumberland’s stock has experienced significant volatility in recent weeks, underscoring the importance of monitoring upcoming developments.
Related Stock Movements (24‑hour snapshot)
| Ticker | Change | Current Price (USD) | Market Capitalisation (USD mn) | P/E Ratio |
|---|---|---|---|---|
| MGYR | –0.6 % | 19.48 | 127.3 | 10.64 |
| ANTX | –0.3 % | 3.56 | 127.6 | — |
| CURN | 0.0 % | 21.66 | 128.8 | 8.31 |
| NKTX | –2.78 % | 1.74 | 128.9 | — |
| ORGO | +2.0 % | 1.02 | 128.6 | — |
Company Overview
Cumberland Pharmaceuticals Inc. is a U.S. healthcare company headquartered in Nashville, Tennessee. The company focuses on acquiring, developing, and marketing prescription products for critical care, emergency medicine, and gastroenterology markets. Cumberland’s stock is listed on the Nasdaq exchange and the company went public in August 2009. Further information is available on the company’s website: www.cumberlandpharma.com .
